OECD Home › Health › Biotechnology policies › Latest Documents
This July 2009 symposium brought together the different communities – scientific, engineering, policy, public and legal – involved in synthetic biology and explored the opportunities and challenges posed by this emerging field.
Workshop discussions were structured around a set of issues papers – one for each of the sessions. The workshop was set up as a working roundtable discussion. 50 participants familiar with data sources for industrial biotechnology attended the workshop.
English, , 287kb
The aim of these guidelines is to propose a harmonised approach for the collection and analysis of biotechnology research and development (R&D) statistics in the government and higher education sectors.
This book reviews how the emergence of pharmacogenetics will impact the efficiency of pharmaceutical R&D and improve healthcare decision making and clinical care. It discusses what policies need to change in order for the public to reap the benefits from advances in diagnostic genetic testin
The ability to effectively use these vast amounts of knowledge will depend in part on the bringing together of different strands of information, data and biological materials within human biobanks and genetic research databases (HBGRDs).
The workshop discussed existing sector, national, or international approaches for assessment of sustainability of bio-based products, such as bio-based chemicals, bio-based plastics, enzymes, bio-based materials, and biofuels.
Synthetic biology is a transformative set of technologies which offer great opportunities for the construction of bioengineered parts, devices and microorganisms.
An OECD workshop hosted by Canada will be held on July 23-24, 2009 in Montréal, Québec immediately after the 6th World Congress on Industrial Biotechnology and Bio-processing to discuss progress over the past 5 years in the methodologies used for sustainability assessment of bio-based products.
English, , 2,570kb
The 2009 edition brings together the latest available economic and activity data on biotechnology and innovation for 22 OECD members and four non-member countries. It builds on the extensive work of the OECD and national experts to improve the comparability of biotechnology statistics.
The impact of biotechnologies on medical research is intensifying. Because of new highly performing technologies, we are better able to understand and explore disease and drug mechanisms, which in turn could lead to major changes in the approach of patient care.